SOPHiA GENETICS (SOPH) to Release Quarterly Earnings on Tuesday

SOPHiA GENETICS (NASDAQ:SOPH) is scheduled to be announcing its earnings results before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings data on Tuesday, March 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.12). The company had revenue of $17.05 million during the quarter, compared to analysts’ expectations of $16.78 million. SOPHiA GENETICS had a negative net margin of 126.63% and a negative return on equity of 47.40%. During the same period last year, the firm earned ($0.22) earnings per share. On average, analysts expect SOPHiA GENETICS to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

SOPHiA GENETICS Stock Performance

Shares of NASDAQ:SOPH opened at $5.00 on Friday. The firm has a market cap of $326.15 million, a PE ratio of -4.10 and a beta of 1.12. The firm’s 50 day simple moving average is $4.93 and its 200-day simple moving average is $4.53. SOPHiA GENETICS has a one year low of $2.13 and a one year high of $7.37.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on SOPH shares. Royal Bank of Canada reissued an “outperform” rating and set a $8.00 price target on shares of SOPHiA GENETICS in a research report on Wednesday, March 6th. BTIG Research increased their target price on shares of SOPHiA GENETICS from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, March 6th.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.